| Literature DB >> 28149052 |
Singaravelu Usha1, Samuel Selvaraj1.
Abstract
The combination of physicochemical properties and energetic parameters derived from protein-ligand complexes play a vital role in determining the biological activity of a molecule. In the present work, protein-ligand interaction energy along with logP values was used to predict the experimental log (IC50) values of 25 different kinase-inhibitors using multiple regressions which gave a correlation coefficient of 0.93. The regression equation obtained was tested on 93 kinase-inhibitor complexes and an average deviation of 0.92 from the experimental log IC50 values was shown. The same set of descriptors was used to predict binding affinities for a test set of five individual kinase families, with correlation values > 0.9. We show that the protein-ligand interaction energies and partition coefficient values form the major deterministic factors for binding affinity of the ligand for its receptor.Entities:
Keywords: Inhibition constant prediction; Kinase inhibitors; Protein-ligand interaction; energetic and solvent descriptors
Year: 2016 PMID: 28149052 PMCID: PMC5267961 DOI: 10.6026/97320630012172
Source DB: PubMed Journal: Bioinformation ISSN: 0973-2063
Experimentally observed and predicted IC50 values for 25 kinase-inhibitor complexes.
| PDB_ID | Ligand_ID | Experimental IC50(nM) | Experimental Log (IC50(nM)) | Predicted log(IC50 (nM)) | |
| Back-check | Jack-knife test | ||||
| 2I6A | 5I5 | 22.8 | 1.36 | 1.33 (0.03) | 1.30(0.06) |
| 2OO8 | RAJ | 1 | 0 | 0.26 (-0.26) | 0.48 (-0.48) |
| 4AT3 | LTI | 4 | 0.6 | 0.28 (0.32) | 0.13 (0.47) |
| 3SXF | BK5 | 5 | 0.7 | 0.69 (0.01) | 0.69 (0.01) |
| 2C1A | I5S | 170 | 2.23 | 1.43 (0.80) | 1.96 (0.27) |
| 3MB6 | 01I | 100 | 2 | 1.71 (0.29) | 1.54 (0.46) |
| 1Y6B | AAX | 38 | 1.58 | 0.85 (0.73) | 1.90 (-0.32) |
| 2A4L | RRC | 400 | 2.6 | 2.82 (-0.22) | 2.90 (-0.30) |
| 2YAK | OSV | 2 | 0.3 | 0.24 (0.07) | 0.17 (0.13) |
| 4GK2 | L66 | 40 | 1.6 | 1.55 (0.05) | 1.53 (0.07) |
| 3POZ | 03P | 23 | 1.36 | 1.65 (-0.28) | 1.91 (-0.55) |
| 4F64 | 0S8 | 63 | 1.8 | 2.00 (-0.20) | 2.15 (-0.35) |
| 3BZ3 | YAM | 1.5 | 0.18 | 0.27 (-0.09) | 0.33 (-0.15) |
| 1Q3D | STU | 15 | 1.18 | 1.28 (-0.11) | 1.34 (-0.16) |
| 3C1X | CKK | 45 | 1.65 | 1.01 (0.64) | 0.68 (0.97) |
| 3D94 | D94 | 19 | 1.28 | 0.96 (0.32) | 0.77 (0.51) |
| 4BKZ | 1WS | 27 | 1.43 | 1.87 (-0.43) | 2.20 (-0.77) |
| 3HRB | I39 | 21 | 1.32 | 1.80 (-0.48) | 1.93 (-0.61) |
| 4BFV | ZVV | 140 | 2.15 | 1.45 (0.70) | 0.54 (1.61) |
| 3LJ3 | WYE | 43 | 1.63 | 2.12 (-0.49) | 2.74 (-1.10) |
| 2VGO | AD5 | 500 | 2.7 | 1.93 (0.77) | 1.39 (1.31) |
| 4HDC | 13Y | 1.2 | 0.08 | 0.37 (-0.29) | 0.77 (-0.69) |
| 1RW8 | 580 | 1320 | 3.12 | 2.96 (0.16) | 2.84 (0.28) |
| 3KRR | DQX | 0.48 | -0.32 | -0.26 (-0.06) | -0.16 (-0.16) |
| 3MVH | WFE | 0.5 | -0.3 | 0.05 (-0.35) | 0.19 (-0.49) |
| Average deviation | 0.41 | 0.63 | |||
| Note: The deviation between the predicted and experimental IC50 values is given in parenthesis. | |||||
Figure 1(a) Scatter plot of experimental and back-check predicted IC50 values in 25 different kinase-inhibitor complexes, (b) Scatter plot of experimental and jack-knife predicted IC50 values in 25 different kinase-inhibitor complexes.
Experimentally observed and predicted IC50 values for 16 mitogen-activated protein kinase-inhibitor complexes
| PDB_ID | LIG_ID | Experimental IC50 (nM) | Experimental log ( IC50 (nM)) | Back-check Prediction |
| 1W82 | L10 | 196 | 2.29 | 2.40 (-0.11) |
| 1WBN | L09 | 350 | 2.54 | 2.20 ( 0.34) |
| 1ZYJ | BI5 | 1500 | 3.18 | 2.84 ( 0.33) |
| 3FLZ | FLZ | 106 | 2.03 | 2.25 (-0.22) |
| 3FMH | 533 | 11 | 1.04 | 1.25 (-0.21) |
| 3HL7 | I47 | 110 | 2.04 | 1.56 ( 0.48) |
| 3HP2 | P36 | 680 | 2.83 | 3.07 (-0.24) |
| 3HRB | I39 | 21 | 1.32 | 1.99 (-0.67) |
| 3IPH | G11 | 316.23 | 2.5 | 2.40 ( 0.10) |
| 3L8X | N4D | 10 | 1 | 0.96 ( 0.04) |
| 3MVM | 39P | 3.9 | 0.59 | 0.63 (-0.03) |
| 3NWW | 3NW | 7 | 0.85 | 0.96 (-0.12) |
| 3S4Q | NK0 | 4 | 0.6 | 0.44 ( 0.16) |
| 3UVP | 48 | 35 | 1.54 | 1.26 ( 0.28) |
| 3ZSG | T75 | 7.1 | 0.85 | 1.15 (-0.30) |
| 4EWQ | GG5 | 600 | 2.78 | 2.62 ( 0.16) |
| Average deviation | 0.29 | |||
| Note: The deviation between the predicted and experimental IC50 values is given in parenthesis. | ||||
Figure 2Scatter plot of experimental and predicted IC50 values in the test set of 93 kinase-inhibitor complexes.
Prediction of experimental log (IC50) values in approved kinase inhibitors.
| S.NO. | PDB ID | Protein name | Ligand ID | Ligand name | Experimental log (IC50 (nM)) | Predicted log (IC50(nM)) |
| 1 | 1M17 | Epidermal growth factor receptor | AQ4 | Erlotinib | - 0.70 – 3.16 (1.23) | 0.87 |
| 2 | 1IEP | Proto-oncogene tyrosine-protein kinase abl | STI | Imatinib | 0.04 – 3.93 (1.99) | 1.79 |
| 3 | 2ITY | Epidermal growth factor receptor | IRE | Gefitinib | 0.00 – 3.44 (1.72) | 1.46 |
| 4 | 2J2I | Proto-oncogene serine/threonine-protein kinase pim-1 | LY4 | Ruboxistaurin | 2.3 | 1.61 |
| 5 | 2GQG | Proto-oncogene tyrosine-protein kinase abl1 | 1N1 | Dasatinib | - 0.70 – 2.85 (1.07) | -0.97 |
| 6 | 2JAV | Serine/threonine-protein kinase nek2 | 5Z5 | Sunitinib | 3.9 | 1.02 |
| 7 | 1UWH | B-raf proto-oncogene serine/threonine-protein kinase | BAX | Sorafenib | 1.04 – 3.86 (2.45) | 1.12 |
| 8 | 1XKK | Epidermal growth factor receptor | FMM | Lapatinib | 0.46 – 2.64 (1.55) | 1.88 |
| 9 | 2F2U | Rho-associated protein kinase 2 | M77 | Fasudil | 2.26 – 4.07 (3.16) | 2.45 |
| Note: The mean value between the logarithm of minimum and maximum experimental IC50 values are given in parenthesis. | ||||||
Experimentally observed and predicted IC50 values for 17 cyclic AMP-dependent protein kinase-inhibitor complexes.
| PDB_ID | LIG_ID | Experimental IC50 (nM) | Experimental log ( IC50 (nM)) | Back-check Prediction |
| 1STC | STU | 51 | 1.71 | 1.45 (0.26) |
| 1SVE | I01 | 5 | 0.7 | 0.99 (-0.29) |
| 1XH4 | R69 | 30 | 1.48 | 1.58 (-0.10) |
| 1YDS | IQS | 5300 | 3.72 | 3.13 (0.59) |
| 2C1A | I5S | 170 | 2.23 | 2.23 (0.00) |
| 2F7X | 4EA | 38 | 1.58 | 1.64 (-0.06) |
| 2GNI | M77 | 7605 | 3.88 | 3.59 (0.29) |
| 2JDS | L20 | 27 | 1.43 | 1.45 (-0.01) |
| 2OH0 | 2PY | 18 | 1.26 | 1.21 (0.04) |
| 2OJF | 4PY | 110 | 2.04 | 2.15 (-0.11) |
| 2UW6 | GVO | 280 | 2.45 | 3.07 (-0.62) |
| 2UZT | SS3 | 14 | 1.15 | 1.11 (0.04) |
| 3L9L | L9L | 167 | 2.22 | 1.78 (0.45) |
| 3MVJ | XFE | 3200 | 3.51 | 3.77 (-0.27) |
| 3OW3 | SMY | 742 | 2.87 | 2.88 (-0.01) |
| 3ZO2 | 15I | 80 | 1.9 | 2.10 (-0.19) |
| 4C35 | NU3 | 560 | 2.75 | 2.76 (-0.01) |
| Average deviation | 0.28 | |||
| Note: The deviation between the predicted and experimental IC50 values is given in parenthesis. | ||||
Figure 3Scatter plot of experimental and back-check predicted IC50 values in (a) 17 cyclic AMP-dependent kinase-inhibitor complexes; (b) 12 caesin kinase-inhibitor complexes; (c) 15 Hepatocyte growth factor receptor kinase-inhibitor complexes; (d)12 cyclin-dependent kinase-inhibitor complexes; (e) 16 mitogen-activated protein kinase-inhibitor complexes.
Experimentally observed and predicted IC50 values for 12 casein kinase-inhibitor complexes.
| PDB_ID | LIG_ID | Experimental IC50 (nM) | Experimental log ( IC50 (nM)) | Back-check Prediction |
| 2QC6 | G12 | 100 | 0.27 | 0.24 (0.03) |
| 2ZJW | REF | 40 | 0.38 | 0.37 (0.01) |
| 3AMY | AGI | 800 | 0.36 | 0.38 (-0.02) |
| 3BQC | EMO | 2000 | 0.18 | 0.20 (-0.03) |
| 3MB6 | 01I | 100 | 0.24 | 0.25 (0.00) |
| 3PE1 | 3NG | 1 | 0.2 | 0.21 (-0.01) |
| 3PWD | CZ0 | 220 | 0.34 | 0.31 (0.03) |
| 3R0T | FU9 | 0.91 | 0.24 | 0.24 (0.01) |
| 3RPS | 4B0 | 320 | 0.36 | 0.37 (-0.01) |
| 3U4U | LNH | 3100 | 0.34 | 0.34 (0.01) |
| 4ANM | WUL | 28 | 0.23 | 0.22 (0.01) |
| 4DGM | AGI | 1200 | 0.22 | 0.23 (-0.02) |
| Average deviation | 0.02 | |||
| Note: The deviation between the predicted and experimental IC50 values is given in parenthesis. | ||||
Experimentally observed and predicted IC50 values for 15 hepatocyte growth factor receptor kinase-inhibitor complexes.
| PDB_ID | LIG_ID | Experimental IC50 (nM) | Experimental log ( IC50 (nM)) | Back-check Prediction |
| 2WD1 | ZZY | 82 | 1.91 | 1.56 (0.36) |
| 2WKM | PFY | 9 | 0.95 | 1.26 (-0.30) |
| 3C1X | CKK | 45 | 1.65 | 1.56 (0.09) |
| 3CCN | LKG | 120 | 2.08 | 1.69 (0.39) |
| 3CD8 | L5G | 9 | 0.95 | 1.11 (-0.16) |
| 3CTH | 319 | 35 | 1.54 | 1.84 (-0.29) |
| 3I5N | B2D | 17 | 1.23 | 1.69 (-0.46) |
| 3F66 | IHX | 900 | 2.95 | 2.88 (0.07) |
| 3L8V | L8V | 8 | 0.9 | 0.72 (0.18) |
| 3QTI | 3QT | 14 | 1.15 | 1.18 (-0.04) |
| 3RHK | M97 | 520 | 2.72 | 2.60 (0.11) |
| 4DEG | 0JJ | 6 | 0.78 | 1.43 (-0.65) |
| 4DEH | 0JK | 612 | 2.79 | 2.71 (0.08) |
| 4EEV | L1X | 42 | 1.62 | 1.09 (0.53) |
| 4GG7 | 0J8 | 6.5 | 0.81 | 0.72 (0.09) |
| Average deviation | 0.31 |
Experimentally observed and predicted IC50 values for 12 cyclin-dependent kinase-inhibitor complexes.
| PDB_ID | LIG_ID | Experimental IC50 (nM) | Experimental log ( IC50 (nM)) | Back-check Prediction |
| 1AQ1 | STU | 7 | 0.85 | 0.71 (0.13) |
| 1DI8 | DTQ | 1000 | 3 | 3.07 (-0.07) |
| 1E1X | NW1 | 2200 | 3.34 | 3.89 (-0.54) |
| 1H01 | FAL | 22000 | 4.34 | 4.74 (-0.40) |
| 1W0X | OLO | 7 | 0.85 | 1.59 (-0.74) |
| 3S2P | PMU | 68 | 1.83 | 1.36 (0.48) |
| 3TIY | TIY | 17000 | 4.23 | 4.36 (-0.13) |
| 3TNW | F18 | 20000 | 4.3 | 3.52 (0.78) |
| 3ULI | 1N3 | 70 | 1.85 | 1.48 (0.37) |
| 3UNJ | 0BX | 11000 | 4.04 | 3.41 (0.63) |
| 3WBL | PDY | 23000 | 4.36 | 4.22 (0.14) |
| 4BGH | 3I6 | 4 | 0.6 | 1.24 (-0.63) |
| Average deviation | 0.49 | |||
| Note: The deviation between the predicted and experimental IC50 values is given in parenthesis. | ||||